Table 1

Details of patients at entry to the study

PatientAge (years)SexDuration of RA (years)ErosiveFunctional classRAPA (ever +)ANA (ever +)Extra-articular featuresDMARD failureDMARD/steroid at entry
* Haemoglobin <120 g/l.
RAPA, rheumatoid arthritis particle agglutination test; ANA, antinuclear antibodies; G, gold; A, azathioprine; S, sulfasalazine; M, methotrexate; H, hydroxychloroquine; D, d-penicillamine; Cy, cyclophosphamide; Ch, chlorambucil; Cya, cyclosporin A; L, leflunomide; P, prednisolone.
157F25+IIIYesNoAnaemia*GASMDPP 7. 5 mg/day
242F21+IIIYesYesAnaemia*GASMDA 100 mg/day
369F40+IIIYesYesGASMDG 50 mg/month
450F11+IIIYesYesAnaemia*GASMPP 10 mg/day
559F17+IIIYesYesNodulesGASMHDM 12.5 mg/week
669F27+IIIYesYesAnaemia*GASMHDA 100 mg/day, P 5 mg/day
755F5+IIYesNoAnaemia*SMHP 5 mg/day
857F11+IINoYesAnaemia*GASMHD
963F13+IIYesNoAnaemia* NodulesGASMA 100 mg/day, G 50 mg/month
1070F18+IIIYesYesAnaemia*GASG 50 mg/month
1160F28+IIIYesYesAnaemia* Sec. AmyloidosisSMDChCyCy 750 mg/month, p 5 mg/day
1269F39+IIYesYesGASMHDM 10 mg/week
1351F15+IIYesNoASMS 3 g/day, A 100 mg/day
1433F17+IIIYesYesAnaemia*GAS
1551F14+IIIYesYesAnaemia* Sjögren's synd.MHM 20 mg/week, H 400 mg/day
1650F20+IVYesYesAnaemia*GASMDCyP 10 mg/day
1754F9+IIIYesYesGASM
1863M20+IIYesYesGHM 20 mg/week, H 400 mg/day
1960M7+IIIYesNoAnaemia* NodulesSMCyM 30 mg/week, Cya 150 mg/day P 10 mg/day
2064F14+IINoNoGASMLp 7.5 mg/day
2149F5+IIIYesYesAnaemia*GASMLP 5 mg/day
2281F23+IIIYesYesSkin vasculitis NodulesGADA 100 mg/day